KR100344156B1 - Cosmetics containing aloe micro capsules - Google Patents
Cosmetics containing aloe micro capsules Download PDFInfo
- Publication number
- KR100344156B1 KR100344156B1 KR1019990065830A KR19990065830A KR100344156B1 KR 100344156 B1 KR100344156 B1 KR 100344156B1 KR 1019990065830 A KR1019990065830 A KR 1019990065830A KR 19990065830 A KR19990065830 A KR 19990065830A KR 100344156 B1 KR100344156 B1 KR 100344156B1
- Authority
- KR
- South Korea
- Prior art keywords
- aloe
- weight
- microcapsules
- skin
- extract
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 239000002537 cosmetic Substances 0.000 title claims abstract description 19
- 235000011399 aloe vera Nutrition 0.000 title claims description 50
- 241001116389 Aloe Species 0.000 title claims description 43
- 239000003094 microcapsule Substances 0.000 title claims description 32
- 229940069521 aloe extract Drugs 0.000 claims abstract description 32
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims abstract description 21
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 claims abstract description 21
- 239000000203 mixture Substances 0.000 claims abstract description 17
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 17
- 239000008213 purified water Substances 0.000 claims abstract description 16
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 claims abstract description 8
- 239000000787 lecithin Substances 0.000 claims abstract description 8
- 235000010445 lecithin Nutrition 0.000 claims abstract description 8
- 229940067606 lecithin Drugs 0.000 claims abstract description 8
- CJPQIRJHIZUAQP-MRXNPFEDSA-N benalaxyl-M Chemical compound CC=1C=CC=C(C)C=1N([C@H](C)C(=O)OC)C(=O)CC1=CC=CC=C1 CJPQIRJHIZUAQP-MRXNPFEDSA-N 0.000 claims abstract description 6
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 claims abstract description 6
- 238000000034 method Methods 0.000 claims description 11
- 239000006071 cream Substances 0.000 claims description 8
- 239000006210 lotion Substances 0.000 claims description 8
- 238000001816 cooling Methods 0.000 claims description 7
- 238000009472 formulation Methods 0.000 claims description 7
- -1 capri triglycerides Chemical class 0.000 claims description 4
- 238000002156 mixing Methods 0.000 claims description 4
- 238000003756 stirring Methods 0.000 claims description 2
- 230000003020 moisturizing effect Effects 0.000 description 24
- 210000003491 skin Anatomy 0.000 description 23
- 230000000052 comparative effect Effects 0.000 description 14
- 239000003921 oil Substances 0.000 description 9
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 8
- 239000012071 phase Substances 0.000 description 8
- 244000144927 Aloe barbadensis Species 0.000 description 7
- 235000002961 Aloe barbadensis Nutrition 0.000 description 7
- 230000000694 effects Effects 0.000 description 7
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 6
- 239000005909 Kieselgur Substances 0.000 description 6
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 6
- 238000004945 emulsification Methods 0.000 description 6
- 239000007788 liquid Substances 0.000 description 6
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 6
- 239000002245 particle Substances 0.000 description 6
- 239000004909 Moisturizer Substances 0.000 description 5
- 210000004027 cell Anatomy 0.000 description 5
- 239000000284 extract Substances 0.000 description 5
- 230000001333 moisturizer Effects 0.000 description 5
- 238000002360 preparation method Methods 0.000 description 5
- 230000008569 process Effects 0.000 description 5
- QFOHBWFCKVYLES-UHFFFAOYSA-N Butylparaben Chemical compound CCCCOC(=O)C1=CC=C(O)C=C1 QFOHBWFCKVYLES-UHFFFAOYSA-N 0.000 description 4
- POJWUDADGALRAB-UHFFFAOYSA-N allantoin Chemical compound NC(=O)NC1NC(=O)NC1=O POJWUDADGALRAB-UHFFFAOYSA-N 0.000 description 4
- 239000008346 aqueous phase Substances 0.000 description 4
- 239000003795 chemical substances by application Substances 0.000 description 4
- 235000011187 glycerol Nutrition 0.000 description 4
- GLDOVTGHNKAZLK-UHFFFAOYSA-N octadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCO GLDOVTGHNKAZLK-UHFFFAOYSA-N 0.000 description 4
- 239000002994 raw material Substances 0.000 description 4
- 230000037394 skin elasticity Effects 0.000 description 4
- 239000004475 Arginine Substances 0.000 description 3
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 3
- 150000004056 anthraquinones Chemical class 0.000 description 3
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 3
- 230000017531 blood circulation Effects 0.000 description 3
- 230000018109 developmental process Effects 0.000 description 3
- KCIDZIIHRGYJAE-YGFYJFDDSA-L dipotassium;[(2r,3r,4s,5r,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl] phosphate Chemical compound [K+].[K+].OC[C@H]1O[C@H](OP([O-])([O-])=O)[C@H](O)[C@@H](O)[C@H]1O KCIDZIIHRGYJAE-YGFYJFDDSA-L 0.000 description 3
- 239000000835 fiber Substances 0.000 description 3
- 238000010438 heat treatment Methods 0.000 description 3
- 230000006872 improvement Effects 0.000 description 3
- 150000002632 lipids Chemical class 0.000 description 3
- 230000014759 maintenance of location Effects 0.000 description 3
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 3
- 239000004292 methyl p-hydroxybenzoate Substances 0.000 description 3
- 229960002216 methylparaben Drugs 0.000 description 3
- 238000006386 neutralization reaction Methods 0.000 description 3
- 230000008929 regeneration Effects 0.000 description 3
- 238000011069 regeneration method Methods 0.000 description 3
- 239000011347 resin Substances 0.000 description 3
- 229920005989 resin Polymers 0.000 description 3
- 210000004927 skin cell Anatomy 0.000 description 3
- 235000013599 spices Nutrition 0.000 description 3
- 239000002562 thickening agent Substances 0.000 description 3
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 2
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 2
- ABEXEQSGABRUHS-UHFFFAOYSA-N 16-methylheptadecyl 16-methylheptadecanoate Chemical compound CC(C)CCCCCCCCCCCCCCCOC(=O)CCCCCCCCCCCCCCC(C)C ABEXEQSGABRUHS-UHFFFAOYSA-N 0.000 description 2
- NIXOWILDQLNWCW-UHFFFAOYSA-N Acrylic acid Chemical compound OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 2
- POJWUDADGALRAB-PVQJCKRUSA-N Allantoin Natural products NC(=O)N[C@@H]1NC(=O)NC1=O POJWUDADGALRAB-PVQJCKRUSA-N 0.000 description 2
- YDQWDHRMZQUTBA-UHFFFAOYSA-N Aloe emodin Chemical compound C1=CC=C2C(=O)C3=CC(CO)=CC(O)=C3C(=O)C2=C1O YDQWDHRMZQUTBA-UHFFFAOYSA-N 0.000 description 2
- ZAKOWWREFLAJOT-CEFNRUSXSA-N D-alpha-tocopherylacetate Chemical compound CC(=O)OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C ZAKOWWREFLAJOT-CEFNRUSXSA-N 0.000 description 2
- 239000003109 Disodium ethylene diamine tetraacetate Substances 0.000 description 2
- 239000004354 Hydroxyethyl cellulose Substances 0.000 description 2
- 229920000663 Hydroxyethyl cellulose Polymers 0.000 description 2
- 229920001214 Polysorbate 60 Polymers 0.000 description 2
- 229920002125 Sokalan® Polymers 0.000 description 2
- HVUMOYIDDBPOLL-XWVZOOPGSA-N Sorbitan monostearate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O HVUMOYIDDBPOLL-XWVZOOPGSA-N 0.000 description 2
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 229960000458 allantoin Drugs 0.000 description 2
- 235000001014 amino acid Nutrition 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 230000000844 anti-bacterial effect Effects 0.000 description 2
- 235000013871 bee wax Nutrition 0.000 description 2
- 229940067596 butylparaben Drugs 0.000 description 2
- 150000001720 carbohydrates Chemical class 0.000 description 2
- 229960001631 carbomer Drugs 0.000 description 2
- ZAIPMKNFIOOWCQ-UEKVPHQBSA-N cephalexin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@@H]3N(C2=O)C(=C(CS3)C)C(O)=O)=CC=CC=C1 ZAIPMKNFIOOWCQ-UEKVPHQBSA-N 0.000 description 2
- ZAKOWWREFLAJOT-UHFFFAOYSA-N d-alpha-Tocopheryl acetate Natural products CC(=O)OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C ZAKOWWREFLAJOT-UHFFFAOYSA-N 0.000 description 2
- SOROIESOUPGGFO-UHFFFAOYSA-N diazolidinylurea Chemical compound OCNC(=O)N(CO)C1N(CO)C(=O)N(CO)C1=O SOROIESOUPGGFO-UHFFFAOYSA-N 0.000 description 2
- 229960001083 diazolidinylurea Drugs 0.000 description 2
- 229940008099 dimethicone Drugs 0.000 description 2
- 239000004205 dimethyl polysiloxane Substances 0.000 description 2
- 235000013870 dimethyl polysiloxane Nutrition 0.000 description 2
- 235000019301 disodium ethylene diamine tetraacetate Nutrition 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- FOYKKGHVWRFIBD-UHFFFAOYSA-N gamma-tocopherol acetate Natural products CC(=O)OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1 FOYKKGHVWRFIBD-UHFFFAOYSA-N 0.000 description 2
- 150000004676 glycans Chemical class 0.000 description 2
- 229940075529 glyceryl stearate Drugs 0.000 description 2
- BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 description 2
- 235000019447 hydroxyethyl cellulose Nutrition 0.000 description 2
- 229910052500 inorganic mineral Inorganic materials 0.000 description 2
- 229940060384 isostearyl isostearate Drugs 0.000 description 2
- 210000002510 keratinocyte Anatomy 0.000 description 2
- 239000011707 mineral Substances 0.000 description 2
- 239000002480 mineral oil Substances 0.000 description 2
- 235000010446 mineral oil Nutrition 0.000 description 2
- 235000013379 molasses Nutrition 0.000 description 2
- GOQYKNQRPGWPLP-UHFFFAOYSA-N n-heptadecyl alcohol Natural products CCCCCCCCCCCCCCCCCO GOQYKNQRPGWPLP-UHFFFAOYSA-N 0.000 description 2
- ZQPPMHVWECSIRJ-KTKRTIGZSA-M oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC([O-])=O ZQPPMHVWECSIRJ-KTKRTIGZSA-M 0.000 description 2
- 229940049964 oleate Drugs 0.000 description 2
- 150000002894 organic compounds Chemical class 0.000 description 2
- 229920000435 poly(dimethylsiloxane) Polymers 0.000 description 2
- 239000001818 polyoxyethylene sorbitan monostearate Substances 0.000 description 2
- 235000010989 polyoxyethylene sorbitan monostearate Nutrition 0.000 description 2
- 229920001282 polysaccharide Polymers 0.000 description 2
- 239000005017 polysaccharide Substances 0.000 description 2
- 229940113124 polysorbate 60 Drugs 0.000 description 2
- 229950011392 sorbitan stearate Drugs 0.000 description 2
- UWHCKJMYHZGTIT-UHFFFAOYSA-N tetraethylene glycol Chemical compound OCCOCCOCCOCCO UWHCKJMYHZGTIT-UHFFFAOYSA-N 0.000 description 2
- 150000003626 triacylglycerols Chemical class 0.000 description 2
- 235000013343 vitamin Nutrition 0.000 description 2
- 239000011782 vitamin Substances 0.000 description 2
- 229940088594 vitamin Drugs 0.000 description 2
- 229930003231 vitamin Natural products 0.000 description 2
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 1
- CQRIWHZHWKQGQD-JWXFUTCRSA-N (2r,3s,4r,5r)-2,3,4,5,6-pentahydroxy-2-methylhexanal Chemical compound O=C[C@@](O)(C)[C@@H](O)[C@H](O)[C@H](O)CO CQRIWHZHWKQGQD-JWXFUTCRSA-N 0.000 description 1
- UFSKIYBOKFBSOA-MLYSRARTSA-N (2r,3s,4s,5r)-2-(hydroxymethyl)-6-octadecoxyoxane-3,4,5-triol Chemical compound CCCCCCCCCCCCCCCCCCOC1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O UFSKIYBOKFBSOA-MLYSRARTSA-N 0.000 description 1
- RMTFNDVZYPHUEF-XZBKPIIZSA-N 3-O-methyl-D-glucose Chemical compound O=C[C@H](O)[C@@H](OC)[C@H](O)[C@H](O)CO RMTFNDVZYPHUEF-XZBKPIIZSA-N 0.000 description 1
- NIXOWILDQLNWCW-UHFFFAOYSA-M Acrylate Chemical compound [O-]C(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-M 0.000 description 1
- 235000007516 Chrysanthemum Nutrition 0.000 description 1
- 240000005250 Chrysanthemum indicum Species 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- AEMOLEFTQBMNLQ-YMDCURPLSA-N D-galactopyranuronic acid Chemical compound OC1O[C@H](C(O)=O)[C@H](O)[C@H](O)[C@H]1O AEMOLEFTQBMNLQ-YMDCURPLSA-N 0.000 description 1
- WQZGKKKJIJFFOK-QTVWNMPRSA-N D-mannopyranose Chemical compound OC[C@H]1OC(O)[C@@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-QTVWNMPRSA-N 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 206010015150 Erythema Diseases 0.000 description 1
- IAJILQKETJEXLJ-UHFFFAOYSA-N Galacturonsaeure Natural products O=CC(O)C(O)C(O)C(O)C(O)=O IAJILQKETJEXLJ-UHFFFAOYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 1
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
- 239000004166 Lanolin Substances 0.000 description 1
- 241000234280 Liliaceae Species 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 229920002230 Pectic acid Polymers 0.000 description 1
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 1
- 241000219295 Portulaca Species 0.000 description 1
- 239000004373 Pullulan Substances 0.000 description 1
- 229920001218 Pullulan Polymers 0.000 description 1
- 108010013296 Sericins Proteins 0.000 description 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
- 229920002385 Sodium hyaluronate Polymers 0.000 description 1
- 235000018936 Vitellaria paradoxa Nutrition 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 150000001335 aliphatic alkanes Chemical class 0.000 description 1
- 125000005250 alkyl acrylate group Chemical group 0.000 description 1
- AFHJQYHRLPMKHU-OSYMLPPYSA-N aloin A Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1[C@@H]1C2=CC(CO)=CC(O)=C2C(=O)C2=C(O)C=CC=C21 AFHJQYHRLPMKHU-OSYMLPPYSA-N 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000002421 anti-septic effect Effects 0.000 description 1
- 235000003704 aspartic acid Nutrition 0.000 description 1
- 229940079894 benzophenone-9 Drugs 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 235000014121 butter Nutrition 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 229960000541 cetyl alcohol Drugs 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 229920006037 cross link polymer Polymers 0.000 description 1
- 201000010251 cutis laxa Diseases 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 230000008260 defense mechanism Effects 0.000 description 1
- 238000001784 detoxification Methods 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- QDCHWIWENYCPIL-UHFFFAOYSA-L disodium;4-hydroxy-5-(2-hydroxy-4-methoxy-5-sulfonatobenzoyl)-2-methoxybenzenesulfonate Chemical compound [Na+].[Na+].C1=C(S([O-])(=O)=O)C(OC)=CC(O)=C1C(=O)C1=CC(S([O-])(=O)=O)=C(OC)C=C1O QDCHWIWENYCPIL-UHFFFAOYSA-L 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 230000002500 effect on skin Effects 0.000 description 1
- 238000000635 electron micrograph Methods 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 231100000321 erythema Toxicity 0.000 description 1
- 239000003797 essential amino acid Substances 0.000 description 1
- 235000020776 essential amino acid Nutrition 0.000 description 1
- 235000004626 essential fatty acids Nutrition 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
- 238000000227 grinding Methods 0.000 description 1
- 229910001385 heavy metal Inorganic materials 0.000 description 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 235000019388 lanolin Nutrition 0.000 description 1
- 229940039717 lanolin Drugs 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 210000002752 melanocyte Anatomy 0.000 description 1
- 208000030159 metabolic disease Diseases 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- LCLHHZYHLXDRQG-ZNKJPWOQSA-N pectic acid Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)O[C@H](C(O)=O)[C@@H]1OC1[C@H](O)[C@@H](O)[C@@H](OC2[C@@H]([C@@H](O)[C@@H](O)[C@H](O2)C(O)=O)O)[C@@H](C(O)=O)O1 LCLHHZYHLXDRQG-ZNKJPWOQSA-N 0.000 description 1
- 229940100460 peg-100 stearate Drugs 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- 239000010318 polygalacturonic acid Substances 0.000 description 1
- 235000013824 polyphenols Nutrition 0.000 description 1
- 235000018102 proteins Nutrition 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 239000001944 prunus armeniaca kernel oil Substances 0.000 description 1
- 235000019423 pullulan Nutrition 0.000 description 1
- 230000008707 rearrangement Effects 0.000 description 1
- 238000004626 scanning electron microscopy Methods 0.000 description 1
- 208000017520 skin disease Diseases 0.000 description 1
- 230000036560 skin regeneration Effects 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229940010747 sodium hyaluronate Drugs 0.000 description 1
- YWIVKILSMZOHHF-QJZPQSOGSA-N sodium;(2s,3s,4s,5r,6r)-6-[(2s,3r,4r,5s,6r)-3-acetamido-2-[(2s,3s,4r,5r,6r)-6-[(2r,3r,4r,5s,6r)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2- Chemical compound [Na+].CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 YWIVKILSMZOHHF-QJZPQSOGSA-N 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 150000003505 terpenes Chemical class 0.000 description 1
- 239000003440 toxic substance Substances 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
- 230000002087 whitening effect Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/02—Cosmetics or similar toiletry preparations characterised by special physical form
- A61K8/11—Encapsulated compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
- A61K8/9783—Angiosperms [Magnoliophyta]
- A61K8/9794—Liliopsida [monocotyledons]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Birds (AREA)
- Dermatology (AREA)
- Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Botany (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Cosmetics (AREA)
Abstract
본 발명은 화장료용 조성물에 관한 것으로, 레시틴 1∼3.00중량%., 에탄올 5∼10.00중량%, 카프릭/카프리 트리글리세라이드 5∼10중량%, 프로필렌 글리콜 5∼10중량% ,알로에 추출물 10∼20중량%, 및 나머지의 정제수로 구성된 것을 특징으로 한다.The present invention relates to a cosmetic composition, 1 to 3.00% by weight of lecithin, 5 to 10.00% by weight of ethanol, 5 to 10% by weight of capric / capri triglyceride, 5 to 10% by weight of propylene glycol, aloe extract 10 to 20 Wt%, and the remaining purified water.
Description
본 발명은 알로에 마이크로캡슐을 포함하는 화장료 조성물에 관한 것으로, 더욱 상세하게는 알로에 추출물을 마이크로 캡슐화하여 생리활성 및 미용효과가 더욱 증진된 알로에를 함유하는 화장료에 관한 것이다.The present invention relates to a cosmetic composition comprising an aloe microcapsules, and more particularly, to a cosmetic containing aloe with microencapsulation of the aloe extract to further enhance the physiological activity and cosmetic effects.
알로에(Aloe)는 백합과(Liliaceae)에 속하는 약용식물로서 다양한 약효로 인하여 고대로부터 민간에 널리 이용되어 왔다. 현재까지 규명된 알로에의 생리활성 및 미용효과는 다음과 같다.Aloe is a medicinal plant belonging to the family Liliaceae and has been widely used in folklore since ancient times due to its various effects. The physiological and cosmetic effects of aloe identified to date are as follows.
1) 혈액 순환 촉진 : 혈액 순환장애로 나타나는 맬라닌 세포의 증가와 그늘진 피부를 모세 혈관의 혈액 순환을 촉진하여 깨끗하고 밝은 피부로 가꾸어줌.1) Promotes blood circulation: Increases the amount of melanocytes and shaded skin, which is caused by blood circulation disorders, promotes blood circulation of capillaries to make clean and bright skin.
2) 신체세포액의 개선과 체내 유독물질의 분해 : 피로나 중금속등의 오염으로부터 방어기작(해독)으로 각종 피부질환이나 대사장애에 대해 미연 방지2) Improvement of body cell fluid and decomposition of toxic substances in body: Preventing various skin diseases and metabolic disorders by defense mechanism (detoxification) from fatigue and heavy metal contamination
3) 체내 항균능력 부여와 살균3) Antibacterial ability and sterilization
4) 세포재생기능 : 생체구성물질로써 각종 필수아노산이나 필수지방산등의 다량함유로 인한 피부영양 공급과 피부재생에 관여4) Cell regeneration function: It is a biological component and is involved in skin nutrition supply and skin regeneration due to the large amount of essential ananoic acid and essential fatty acids.
5) 피부보습증진 : 천연 다당체의 피부보습증진 효과5) Skin moisturizing enhancement: Skin moisturizing effect of natural polysaccharides
6) 피부탄력증진 : 느슨해진 피부세포에 영양물질 공급 또는 피부세포재생으로 인한 세포간의 구조적 재배열을 이끌어 피부탄력증진6) Skin elasticity enhancement: Skin elasticity is enhanced by supplying nutrients to loose skin cells or structural rearrangement between cells due to skin cell regeneration.
7) 자외선 흡수기능 : 유기 화합물, 미네랄, 비타민, 안트라퀴논 등의 작용으로 자외선 흡수 및 자외선으로 인한 손상된 피부회복7) Ultraviolet absorption function: Absorbs ultraviolet rays and recovers damaged skin due to the action of organic compounds, minerals, vitamins, anthraquinones, etc.
8) 미백기능8) Whitening function
이러한 기능을 나타내게 하는 알로에의 성분들은 다음과 같다.The components of aloe that show this function are as follows.
1)글루코프로테인(glucoproteins) -----------암, 염증, 홍반에 효과1) Glucoproteins ----------- Effects on cancer, inflammation and erythema
알렉신(alexin) a., 알렉신 b.Alexin a., Alexin b.
2)페놀류(phenolics) -----------의약적 작용, 방부, 항세균, 항생물질, 항염증2) phenolics ----------- Medical action, antiseptic, antibacterial, antibiotic, anti-inflammatory
알로에 에모딘(aloe emodin), 바르발린(barbalin), 크리소파닐(chrysophanil), 아나트라놀(anathranol), 알로에신(aloesin), 안트라퀴논(anthraquinones)Aloe emodin, barbalin, chrysophanil, anathranol, aloesine, anthraquinones
3)다당류(poly saccharides) ---------- 보습작용, 피부탄력3) polysaccharides ---------- Moisturizing, skin elasticity
글루코즈, 만노즈, 갈락투론산(galacturonic acid), 글루코만닌(glucomannins), 펙트산(pectic acid)Glucose, mannose, galacturonic acid, glucomannins, pectic acid
4)아미노산류 ------------ 생체 세포구성에 있어서 꼭 필요한 필수 아미노산으로 세포의 재생 및 성장에 효과4) Amino Acids ------------ Essential amino acids essential for cell composition.
라이신, 히스티딘, 아르기닌, 아스파르트산, 세린, 글루타민 등 20∼22종의 아미노산 함유Contains 20 to 22 amino acids such as lysine, histidine, arginine, aspartic acid, serine, and glutamine
5)지질류 --------- 세포의 구성성분으로 피부 세포의 재생 성장에 관여5) Lipids --------- Cell constituents involved in the regeneration of skin cells
이소프레노이드류(isoprenoids), 알칸류, n-알킬 알코올류, 지방산Isoprenoids, alkanes, n-alkyl alcohols, fatty acids
6)단백질 7)유기 화합물 8)미네랄류(Na, K, Mg, Ca 등) 9)비타민류 10)안트라퀴논 11)레시틴 12) 효소6) Proteins 7) Organic Compounds 8) Minerals (Na, K, Mg, Ca, etc.) 9) Vitamins 10) Anthraquinones 11) Lecithin 12) Enzymes
그러나, 이러한 다양한 효능에도 불구하고, 알로에를 그대로 추출한 엑기스 상태로 화장료에 첨가 한 경우, 피부 경피에 흡수되는 부분이 적고 손실도가 커서 그 효능을 제대로 발휘할 수가 없었다.However, in spite of such various effects, when aloe is extracted as it is, it is added to the cosmetics, the portion absorbed by the dermal transdermal and loss is too large to show its efficacy.
따라서, 본 발명의 목적은 경피 손실도가 적은 캡슐화된 알로에를 함유하는 화장료용 조성물을 제공하는 것이다.Accordingly, it is an object of the present invention to provide a cosmetic composition containing encapsulated aloe with low transdermal loss.
본 발명의 다른 목적은 알로에를 콤플렉스화하여 세포간지질과 유사구조로 마이크로 캡슐화시킴으로써 보습, 피부탄력 증진 등 알로에의 효능을 충분히 발휘할 수 있도록 하는 것이다.Another object of the present invention is to complex the aloe to microencapsulate the intercellular lipid and the similar structure to fully exhibit the effects of aloe, such as moisturizing, skin elasticity enhancement.
도 1은 알로에 마이크로 캡슐의 입자 크기 분포도1 is a particle size distribution diagram of aloe microcapsules
도 2은 알로에 마이크로 캡슐의 전자 현미경 사진2 is an electron micrograph of aloe microcapsules
도 3은 알로에 마이크로 캡슐의 보습력을 공지 보습제의 보습력과 비교한 그래프.Figure 3 is a graph comparing the moisturizing power of the aloe microcapsules with the moisturizing power of known moisturizing agents.
도 4는 알로에 마이크로 캡슐을 사용한 경우의 피부 경피 수분 손실도를 공지 보습제를 사용한 경우의 피부 경피 수분 손실도와 비교한 그래프.Figure 4 is a graph comparing the skin transdermal moisture loss with aloe microcapsules when using a known moisturizer.
도 5는 알로에 마이크로 캡슐을 사용하기 전 후의 피부 이미지 분석기 사진.5 is a skin image analyzer photograph before and after using aloe microcapsules.
도 6는 스킨에 본 발명의 캡슐화된 알로에 추출물과 캡슐화되지 않은 알로에 추출물을 첨가한 경우 보습력을 비교한 그래프.Figure 6 is a graph comparing the moisturizing power when added to the encapsulated aloe extract and unencapsulated aloe extract of the present invention to the skin.
도 7은 크림에 본 발명의 캡슐화된 알로에 추출물과 캡슐화되지 않은 알로에 추출물을 첨가한 경우 보습력을 비교한 그래프.Figure 7 is a graph comparing the moisturizing power when added to the encapsulated aloe extract and unencapsulated aloe extract of the present invention to the cream.
도 8은 로션에 본 발명의 캡슐화된 알로에 추출물과 캡슐화되지 않은 알로에 추출물을 첨가한 경우 보습력을 비교한 그래프.8 is a graph comparing the moisturizing power when the encapsulated aloe extract and the unencapsulated aloe extract of the present invention are added to a lotion.
상기 본 발명의 목적은 레시틴 1∼3.00중량%., 에탄올 5∼10.00중량%, 카프릭/카프리 트리글리세라이드 5∼10중량%, 프로필렌 글리콜 5∼10중량% ,알로에 추출물 10∼20중량%, 및 나머지의 정제수로 구성된 화장료용 조성물에 의해 달성된다.The object of the present invention is 1 to 3.00% by weight of lecithin, 5 to 10.00% by weight of ethanol, 5 to 10% by weight of capric / capri triglyceride, 5 to 10% by weight of propylene glycol, 10 to 20% by weight of aloe extract, and It is achieved by the cosmetic composition consisting of the remaining purified water.
본 발명의 화장료 조성물은 다음의 방법으로 제조된다.The cosmetic composition of the present invention is prepared by the following method.
우선, 알로에 베라(Aloe Vera)생잎을 정제수에 깨끗이 세척한후 박피하여(외피제거) 알로에 베라 겔(Aloe Vera Gel)을 얻는다. 알로에 베라 겔를 잘게 분쇄한후 약 70∼80℃로 가열하여 규조토에 1차여과하여 섬유질을 제거한다. 이때 얻어진 불투명 알로에 베라 겔을 95℃에서 40분간 가열하면서 활성탄으로 2차여과한 후 규조토로 3차여과하여 투명 액상의 알로에 추출물을 얻는다. 이 투명 액상의 알로에추출물을 100℃에서 20분간 멸균처리하여 본 발명의 화장료 조성물 제조에 사용한다.First, aloe vera (Aloe Vera) fresh leaves are washed with purified water and then peeled (development) to obtain an Aloe Vera Gel (Aloe Vera Gel). After grinding the aloe vera gel finely and heated to about 70 ~ 80 ℃ by primary filtration on diatomaceous earth to remove the fiber. The opaque aloe vera gel obtained at this time was filtered secondly with activated carbon while heating at 95 ° C. for 40 minutes, followed by third filtration with diatomaceous earth to obtain a transparent liquid aloe extract. This transparent liquid aloe extract is sterilized at 100 ° C. for 20 minutes to be used for preparing the cosmetic composition of the present invention.
레시틴, 에탄올, 카프릭/카프리 트리글리세라이드, 프로필렌 글리콜, 정제수및 상기 방법으로 추출된 알로에를 혼합, 교반하여 미세 균질기를 통과 시킨후 냉각, 탈포함으로써 알로에 추출물을 캡슐화시킨다. 이렇게 캡슐화된 알로에 추출물을 이하 '알로에 마이크로캡슐'이라 부른다.Lecithin, ethanol, capric / capri triglyceride, propylene glycol, purified water and aloe extracted by the above method are mixed and stirred to pass through a fine homogenizer, followed by cooling and defoaming to encapsulate the aloe extract. The aloe extract thus encapsulated is called aloe microcapsules.
본 발명의 화장료 조성물을 이용하여 각 화장품 제형을 제조하는 경우, 스킨은 본 발명의 알로에 마이크로캡슐을 스킨 원료와 실온에서 균일하게 혼합하고 교반하여 제조하고, 로션이나 크림은 일반 유화방법으로 오일에 용해되는 성분을 유상성분으로, 정제수에 용해되는 성분을 수상성분으로 하여 일정온도(75-80℃)에서 수상성분과 유상성분을 일반 호모믹서로 균질혼합하는 유화공정을 거쳐, 증점제인 수지 성분의 중화를 한 다음 냉각후, 알로에 마이크로캡슐 첨가, 탈포과정을 거쳐 제조를 완료한다. 각 제형에 첨가되는 본 발명의 화장료 조성물의 양은 10-20중량%가 바람직하다.When preparing each cosmetic formulation using the cosmetic composition of the present invention, the skin is prepared by uniformly mixing and stirring the aloe microcapsules of the present invention with the skin raw material at room temperature, and the lotion or cream is dissolved in oil by a general emulsification method. Neutralization of the resin component as a thickener through an emulsification process that homogeneously mixes the aqueous phase component and the oil phase component with a general homomixer at a predetermined temperature (75-80 ° C) using an ingredient that becomes an oil phase component and a component dissolved in purified water as an aqueous phase component. After cooling, the preparation is completed by adding aloe microcapsules and defoaming. The amount of the cosmetic composition of the present invention added to each formulation is preferably 10-20% by weight.
이하, 실시예를 통하여 본 발명을 보다 상세하게 설명한다.Hereinafter, the present invention will be described in more detail with reference to Examples.
실시예 1 알로에 마이크로 캡슐의 제조Example 1 Preparation of Aloe Microcapsules
알로에 베라(Aloe Vera)생잎 1kg을 정제수에 깨끗이 세척한후 박피하여(외피제거) 알로에 베라 겔(Aloe Vera Gel)을 얻었다. 알로에 베라 겔를 잘게 분쇄한후 75℃로 가열하여 규조토에 1차여과하여 섬유질을 제거하였다. 얻어진 알로에 베라 겔을 95℃에서 40분간 가열하면서 활성탄으로 2차여과한 후 규조토로 3차여과하여 투명 액상의 알로에 추출물을 얻었다. 이 투명 액상의 알로에 추출물을 100℃에서 20분간 멸균처리하였다. 멸균 처리한 알로에 추출물을 15g 평량한 후, 레시틴 2g, 에탄올 8g, 카프릭/카프리 트리글리세라이드 7.5g, 프로필렌 글리콜 7.5g, 및 정제수 60g을 혼합, 교반하여 미세 균질기를 통과 시킨후 냉각, 탈포시켰다.Aloe Vera (Aloe Vera) fresh leaves 1kg was washed with purified water and then peeled (development) to obtain an Aloe Vera Gel (Aloe Vera Gel). The aloe vera gel was finely pulverized and heated to 75 ° C. to first filter the diatomaceous earth to remove fibers. The resulting aloe vera gel was secondly filtered with activated carbon while heating at 95 ° C. for 40 minutes, and then thirdly with diatomaceous earth to obtain a transparent liquid aloe extract. This transparent liquid aloe extract was sterilized at 100 ° C. for 20 minutes. After weighing 15g of the sterilized aloe extract, 2g of lecithin, 8g of ethanol, 7.5g of capric / capri triglyceride, 7.5g of propylene glycol, and 60g of purified water were mixed and stirred to pass through a fine homogenizer, followed by cooling and defoaming.
얻어진 알로에 마이크로 캡슐의 입자분포를 MALVERN, PCS 4700를 이용해서 측정한 결과 입자 크기는 0.05-1.00μ였다(도 1). 입자의 크기가 너무 미세하여 일반적인 광학 현미경으로는 측정이 불가능하므로, 동결 전자 현미경을 이용하여 찍은 알로에 마이크로 캡슐의 입자사진(PHOTOGRAPHING FREEZE-FRACTURE SCANNING ELECTRON MICROSCOPY)을 도 2에 게시하였다.The particle size of the obtained aloe microcapsules was measured using MALVERN and PCS 4700, and the particle size was 0.05-1.00 mu (Fig. 1). Since the size of the particles is too small to be measured by a general optical microscope, a photograph of particles of aloe microcapsule (PHOTOGRAPHING FREEZE-FRACTURE SCANNING ELECTRON MICROSCOPY) taken using a frozen electron microscope is shown in FIG. 2.
실시예 2 보습력 측정 시험Example 2 Moisturizing Force Test
공지의 보습제(탄수화물복합체, 글리세린)와 실시예 1에서 제조된 알로에 마이크로 캡슐을 각각 바른 후 CORNEOMETER로 보습력을 측정한 결과를 도 3에 도시하였다. 보습력이 우수한 다른 보습제(탄수화물복합체, 글리세린)와 비교시 알로에 마이크로 캡슐이 보습력이 더 우수함을 알수 있었다.3 shows the results of measuring the moisturizing power with CORNEOMETER after applying a known moisturizer (carbohydrate complex, glycerin) and the aloe microcapsules prepared in Example 1, respectively. Compared with other moisturizing agents (carbohydrate complex, glycerin), the aloe microcapsules showed better moisturizing power.
실시예 3 피부 경피 수분 손실도 측정 시험Example 3 Skin Transdermal Water Loss Measurement Test
공지의 보습제(당밀 추출물, 마치현추출물)와 실시예 1에서 제조된 알로에 마이크로 캡슐을 각각 바른 후 TEWAMETER TM210으로 경피 수분 손실을 보습제를 바르지 않은 경우와 비교 측정한 결과를 도 4에 도시하였다. 알로에 마이크로캡슐이 다른 보습제(당밀 추출물, 마치현추출물)에 비해 경피 수분 손실이 적음을 알수 있었다.4 shows a result of measuring the percutaneous moisture loss with a moisturizer with TEWAMETER TM210 after applying a known moisturizing agent (molasses extract, portulaca extract) and the aloe microcapsules prepared in Example 1, respectively. Aloe microcapsules showed less loss of transdermal moisture than other moisturizers (molasses extract, guchi extract).
실시예 4 피부개선도 측정 시험Example 4 Skin Improvement Test
IMAGE ANALYZER를 이용해서 실시에 1에서 제조한 알로에 마이크로 캡슐을 바르기 전과 바른 1주일 후의 사진을 촬영하여 그 결과를 도 5에 도시하였다. 알로에마이크로 캡슐을 바르기 전에 거치른 각질이 바른후에 완전히 없어졌음을 알 수 있었다.Photographs were taken before and after 1 week of application of the aloe microcapsules prepared in Example 1 using IMAGE ANALYZER, and the results are shown in FIG. 5. Before applying aloe microcapsules, the dead skin was completely removed after application.
실시예 5 및 비교예 1 : 스킨 제조Example 5 and Comparative Example 1: Skin Preparation
알로에 베라(Aloe Vera)생잎 1kg을 정제수에 깨끗이 세척한후 박피하여(외피제거) 알로에 베라 겔(Aloe Vera Gel)을 얻었다. 알로에 베라 겔를 잘게 분쇄한후 70℃로 가열하여 규조토에 1차여과하여 섬유질을 제거하였다. 얻어진 알로에 베라 겔을 95℃에서 40분간 가열하면서 활성탄으로 2차여과한 후 규조토로 3차여과하여 투명 액상의 알로에 추출물을 얻었다. 이 투명 액상의 알로에 추출물을 100℃에서 20분간 멸균처리하였다.Aloe Vera (Aloe Vera) fresh leaves 1kg was washed with purified water and then peeled (development) to obtain an Aloe Vera Gel (Aloe Vera Gel). The aloe vera gel was finely pulverized, heated to 70 ° C., and filtered first with diatomaceous earth to remove fibers. The resulting aloe vera gel was secondly filtered with activated carbon while heating at 95 ° C. for 40 minutes, and then thirdly with diatomaceous earth to obtain a transparent liquid aloe extract. This transparent liquid aloe extract was sterilized at 100 ° C. for 20 minutes.
멸균 처리한 알로에 추출물을 하기 표 1의 스킨 제형 비율 대로 실온에서 혼합하고 교반하여 스킨을 제조하였다(비교예 1).Sterile treated aloe extract was mixed and stirred at room temperature according to the skin formulation ratio of Table 1 below to prepare a skin (Comparative Example 1).
또, 멸균 처리한 알로에 추출물을 20g 평량한 후, 레시틴 2g, 에탄올 8g, 카프릭/카프리 트리글리세라이드 7.5g, 프로필렌 글리콜 7.5g, 및 정제수 55g을 혼합, 교반하여 미세 균질기를 통과 시킨후 냉각, 탈포시켰다.After 20g of the sterilized aloe extract was weighed, 2g of lecithin, 8g of ethanol, 7.5g of capric / capri triglyceride, 7.5g of propylene glycol, and 55g of purified water were mixed and stirred to pass through a fine homogenizer, followed by cooling and defoaming. I was.
이 마이크로 캡슐을 하기 표 1의 스킨 제형 비율 대로 실온에서 혼합하고 교반하여 스킨을 제조하였다(실시예 5).The microcapsules were mixed and stirred at room temperature according to the skin formulation ratio of Table 1 below to prepare skins (Example 5).
표 1Table 1
실시예 5와 비교예 1의 스킨을 각각 바른후 보습력을 CORNEOMETER로 측정한 결과를 도 6에 도시하였다. 알로에 마이크로캡슐을 첨가한 스킨이 일반 알로에 추출물을 첨가한 스킨보다 보습력이 우수함을 알수 있었다.After applying the skins of Example 5 and Comparative Example 1 respectively, the result of measuring the moisture retention power by CORNEOMETER is shown in FIG. 6. The skin added with aloe microcapsules showed better moisturizing power than the skin added with aloe extract.
실시예 6 및 비교예 2:크림 제조Example 6 and Comparative Example 2: Cream Preparation
실시예 5 및 비교예과 동일한 방법으로 알로에 추출액 및 알로에 마이크로 캡슐을 제조하였다.Aloe extract and aloe microcapsules were prepared in the same manner as in Example 5 and Comparative Example.
하기 표 2의 제형 비율을 사용하여 일반 유화방법으로 오일에 용해되는 성분을 유상성분으로, 정제수에 용해되는 성분을 수상성분으로 하여 80℃에서 수상성분과 유상성분을 일반 호모믹서로 균질혼합하는 유화공정을 거쳐, 증점제인 수지 성분의 중화를 한 다음 냉각 후, 멸균 처리한 알로에 추출물(비교예 2) 및 알로에 마이크로 캡슐(실시예 6)을 각각 첨가하여, 탈포과정을 거쳐 크림을 제조하였다.Emulsification of homogeneous mixing of the aqueous phase component and the oil phase component with a general homomixer at 80 ° C. by using the formulation ratio shown in Table 2 below as a oil phase component and a component dissolved in purified water as an oil phase component using a general emulsification method. After the process, neutralization of the resin component as a thickener, and after cooling, sterilized aloe extract (Comparative Example 2) and aloe microcapsules (Example 6) were added, respectively, to prepare a cream through a defoaming process.
표 2TABLE 2
실시예 6과 비교예 2의 크림을 각각 바른후 보습력을 CORNEOMETER로 측정한 결과를 도 7에 도시하였다. 알로에 마이크로캡슐을 첨가한 크림이 일반 알로에 추출물을 첨가한 크림보다 보습력이 우수함을 알수 있었다.After applying the cream of Example 6 and Comparative Example 2, respectively, the result of measuring the moisture retention power by CORNEOMETER is shown in FIG. Cream with aloe microcapsules was found to be more moisturizing than cream with aloe extract.
실시예 7 및 비교예 3:로션 제조Example 7 and Comparative Example 3: Lotion Preparation
실시예 5 및 비교예과 동일한 방법으로 알로에 추출액 및 알로에 마이크로 캡슐을 제조하였다.Aloe extract and aloe microcapsules were prepared in the same manner as in Example 5 and Comparative Example.
하기 표 3의 제형 비율을 사용하여 일반 유화방법으로 오일에 용해되는 성분을 유상성분으로, 정제수에 용해되는 성분을 수상성분으로 하여 75℃에서 수상성분과 유상성분을 일반 호모믹서로 균질혼합하는 유화공정을 거쳐, 증점제인 수지 성분의 중화를 한 다음 냉각 후, 멸균 처리한 알로에 추출물(비교예 3) 및 알로에 마이크로 캡슐(실시예 7)을 각각 첨가하여, 탈포과정을 거쳐 로션을 제조하였다.Emulsification of homogeneous mixing of the aqueous phase component and the oil phase component with a general homomixer at 75 ° C. using the formulation ratio shown in Table 3 below as a oil phase component and a component dissolved in purified water as an oil phase component using a general emulsification method. After the process, neutralization of the resin component as a thickener, and after cooling, sterilized aloe extract (Comparative Example 3) and aloe microcapsules (Example 7) were added, respectively, to prepare a lotion through a defoaming process.
표 3TABLE 3
실시예 7과 비교예 3의 로션을 각각 바른후 보습력을 CORNEOMETER로 측정한 결과를 도 8에 도시하였다. 알로에 마이크로캡슐을 첨가한 로션이 일반 알로에 추출물을 첨가한 로션보다 보습력이 우수함을 알수 있었다.After applying the lotion of Example 7 and Comparative Example 3, respectively, the result of measuring the moisture retention power by CORNEOMETER is shown in FIG. Lotion added with aloe microcapsules was found to be more moisturizing than lotion added with aloe extract.
알로에를 마이크로 캡슐화 한 본 발명의 화장료 조성물은 다른 보습제와 비교해서 월등히 보습력과 피부 개선도가 뛰어나며 일반 에멀젼에 함유되어서도 보습효과가 매우 뛰어나다. 또한 세포간지질사이의 거리가 100-200나노미터인데 본 발명의 알로에 마이크로 캡슐레이션 입자의 크기가 0.05-1.00μ이므로 각질세포에 매우 빠르게 침투하여 알로에의 다양한 효능을 극대화시킬 수 있으며 각질세포간지질내의 보습, 각질세포내보습, 수분보유능력의 보습막을 형성하는 것이 다른 어떤 보습제에 비해서도 우수하다.The cosmetic composition of the present invention microencapsulated aloe is superior to other moisturizers, excellent moisturizing power and skin improvement, and even in the general emulsion, it is very excellent moisturizing effect. In addition, the distance between the intercellular lipids is 100-200 nanometers, the size of the aloe microcapsulation particles of the present invention is 0.05-1.00μ, so it can penetrate keratinocytes very quickly to maximize the various effects of aloe and within Moisturizing, keratinocyte moisturizing, and water-forming moisturizing film is superior to any other moisturizing agents.
Claims (4)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1019990065830A KR100344156B1 (en) | 1999-12-30 | 1999-12-30 | Cosmetics containing aloe micro capsules |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1019990065830A KR100344156B1 (en) | 1999-12-30 | 1999-12-30 | Cosmetics containing aloe micro capsules |
Publications (2)
Publication Number | Publication Date |
---|---|
KR20010058496A KR20010058496A (en) | 2001-07-06 |
KR100344156B1 true KR100344156B1 (en) | 2002-07-24 |
Family
ID=19632998
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1019990065830A Expired - Fee Related KR100344156B1 (en) | 1999-12-30 | 1999-12-30 | Cosmetics containing aloe micro capsules |
Country Status (1)
Country | Link |
---|---|
KR (1) | KR100344156B1 (en) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR101517940B1 (en) * | 2013-05-30 | 2015-05-06 | 주식회사김정문알로에 | Method for manufacturing aloe gel modified by PEG(polyethylen glycol) using DIS(dewatering and impregnation soaking) process and cosmetic composition for moisturizing effect on skin including aloe gel modified by PEG manufactured thereby |
KR101520642B1 (en) * | 2013-02-07 | 2015-05-18 | 주식회사김정문알로에 | Aloe gel microcapsule suspension, preparation thereof and cosmetic composition comprising same |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR102360585B1 (en) * | 2018-12-26 | 2022-02-09 | 한국콜마주식회사 | Method for preparilng aloe extract comprising high concentration of phenolic compound and skin regeneration, anti-inflammatory and/or anti-oxidant composition comprising the same |
Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH03287524A (en) * | 1990-04-03 | 1991-12-18 | Kansai Kouso Kk | Bathing agent |
WO1998007406A1 (en) * | 1996-08-21 | 1998-02-26 | The Procter & Gamble Company | Skin lightening compositions |
WO1998052538A1 (en) * | 1997-05-22 | 1998-11-26 | The Procter & Gamble Company | Cleansing products with improved moisturization |
WO1998052533A1 (en) * | 1997-05-23 | 1998-11-26 | The Procter & Gamble Company | Skin care compositions and method of improving skin appearance |
KR19990088175A (en) * | 1998-05-11 | 1999-12-27 | 에프. 아. 프라저, 에른스트 알테르 (에. 알테르), 한스 페터 비틀린 (하. 페. 비틀린), 피. 랍 보프, 브이. 스펜글러, 페. 아에글러 | Use of nanodispersions in cosmetic end formulations |
KR19990087559A (en) * | 1996-03-05 | 1999-12-27 | 레이서 제이코버스 코넬리스 | Skin protection composition |
KR19990087558A (en) * | 1996-03-05 | 1999-12-27 | 레이서 제이코버스 코넬리스 | Skin protection composition |
-
1999
- 1999-12-30 KR KR1019990065830A patent/KR100344156B1/en not_active Expired - Fee Related
Patent Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH03287524A (en) * | 1990-04-03 | 1991-12-18 | Kansai Kouso Kk | Bathing agent |
KR19990087559A (en) * | 1996-03-05 | 1999-12-27 | 레이서 제이코버스 코넬리스 | Skin protection composition |
KR19990087558A (en) * | 1996-03-05 | 1999-12-27 | 레이서 제이코버스 코넬리스 | Skin protection composition |
WO1998007406A1 (en) * | 1996-08-21 | 1998-02-26 | The Procter & Gamble Company | Skin lightening compositions |
WO1998052538A1 (en) * | 1997-05-22 | 1998-11-26 | The Procter & Gamble Company | Cleansing products with improved moisturization |
WO1998052533A1 (en) * | 1997-05-23 | 1998-11-26 | The Procter & Gamble Company | Skin care compositions and method of improving skin appearance |
KR19990088175A (en) * | 1998-05-11 | 1999-12-27 | 에프. 아. 프라저, 에른스트 알테르 (에. 알테르), 한스 페터 비틀린 (하. 페. 비틀린), 피. 랍 보프, 브이. 스펜글러, 페. 아에글러 | Use of nanodispersions in cosmetic end formulations |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR101520642B1 (en) * | 2013-02-07 | 2015-05-18 | 주식회사김정문알로에 | Aloe gel microcapsule suspension, preparation thereof and cosmetic composition comprising same |
KR101517940B1 (en) * | 2013-05-30 | 2015-05-06 | 주식회사김정문알로에 | Method for manufacturing aloe gel modified by PEG(polyethylen glycol) using DIS(dewatering and impregnation soaking) process and cosmetic composition for moisturizing effect on skin including aloe gel modified by PEG manufactured thereby |
Also Published As
Publication number | Publication date |
---|---|
KR20010058496A (en) | 2001-07-06 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN108904302B (en) | Water-soluble fullerene external composition | |
CN109966186B (en) | Soothing and moisturizing repairing composition containing mineral hot spring | |
JP2935518B2 (en) | Hydration incorporating the extract of sapilla herbs or at least one component of this extract, and in particular a dermatological composition consisting of an antiallergic, antiinflammatory, antiaging composition, a cosmetic or pharmaceutical composition Compositions based on lipid lamellar phases or liposomes | |
CN108969446B (en) | Infant anti-chap skin care composition for enhancing skin barrier function and preparation method thereof | |
EP2731582B1 (en) | Charge providers for a vesicular carrier system of a uv protection composition for the skin or hair | |
DE10226990A1 (en) | Topically applicable micro-emulsions with binary phase and active substance differentiation, their production and their use, in particular for supplying the skin with bioavailable oxygen | |
KR19980018315A (en) | Composition for enhancing production capacity of hyaluronic acid and preparation method thereof | |
CN111329885B (en) | Pharmaceutical composition and cosmetic composition for improving or preventing symptoms of high altitude red, preparation method of pharmaceutical composition and cosmetic | |
EP3589302A1 (en) | Oat lipid extract | |
DE102004020060B3 (en) | Cosmetic skin treatment before, during and after sun exposure involves use of a set of specified pre-sun, sun and after-sun products | |
US20030072816A1 (en) | Agents improving skin barrier function | |
CN101322750B (en) | Novel use of Cistanche tubulosa extract | |
CN117045523A (en) | High-content azelaic acid composition and preparation method thereof | |
CN108852865A (en) | A kind of fullerene topical composition | |
DE19730408B4 (en) | Composition for external use | |
JP3480952B2 (en) | External preparation for skin | |
KR100344156B1 (en) | Cosmetics containing aloe micro capsules | |
US5518722A (en) | Skin regenerating cosmetic composition | |
DE102011057030A1 (en) | Composition containing a tocopherol phosphate, and manufacturing method | |
CN108113924A (en) | A kind of composite plant Shu Min agent and preparation method and application | |
JPH08268859A (en) | Wrinkle prevention / improvement cosmetics | |
JPH11349435A (en) | Skin agent used for external use and effective for preventing and improving pigmentary symptom caused by ultraviolet light | |
DE69823963T2 (en) | DERMATOLOGICAL COMPOSITIONS FOR BLEACHING THE SKIN | |
EP2100592A1 (en) | Cosmetic product with anti-aging effect | |
KR100574233B1 (en) | Cosmetic composition containing plant extracts having skin moisturizing and anti-irritant effects |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A201 | Request for examination | ||
PA0109 | Patent application |
Patent event code: PA01091R01D Comment text: Patent Application Patent event date: 19991230 |
|
PA0201 | Request for examination | ||
PG1501 | Laying open of application | ||
E902 | Notification of reason for refusal | ||
PE0902 | Notice of grounds for rejection |
Comment text: Notification of reason for refusal Patent event date: 20020129 Patent event code: PE09021S01D |
|
E701 | Decision to grant or registration of patent right | ||
PE0701 | Decision of registration |
Patent event code: PE07011S01D Comment text: Decision to Grant Registration Patent event date: 20020507 |
|
GRNT | Written decision to grant | ||
PR0701 | Registration of establishment |
Comment text: Registration of Establishment Patent event date: 20020629 Patent event code: PR07011E01D |
|
PR1002 | Payment of registration fee |
Payment date: 20020702 End annual number: 3 Start annual number: 1 |
|
PG1601 | Publication of registration | ||
PR1001 | Payment of annual fee |
Payment date: 20050617 Start annual number: 4 End annual number: 4 |
|
PR1001 | Payment of annual fee |
Payment date: 20060623 Start annual number: 5 End annual number: 5 |
|
PR1001 | Payment of annual fee |
Payment date: 20070323 Start annual number: 6 End annual number: 6 |
|
PR1001 | Payment of annual fee |
Payment date: 20080625 Start annual number: 7 End annual number: 7 |
|
PR1001 | Payment of annual fee |
Payment date: 20090630 Start annual number: 8 End annual number: 8 |
|
FPAY | Annual fee payment |
Payment date: 20100629 Year of fee payment: 9 |
|
PR1001 | Payment of annual fee |
Payment date: 20100629 Start annual number: 9 End annual number: 9 |
|
LAPS | Lapse due to unpaid annual fee | ||
PC1903 | Unpaid annual fee |